Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline for first-line treatment of ocular adnexal marginal zone lymphoma
2024-513426-29-00Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxycycline in marginal zone B-cell lymphoma (MZL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: 2-year progression-free survival. Started Jan 2025; status: completed.
02
Drugs
doxycycline
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2024-513426-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513426-29-00.